Long-Term Safety of Anti-TNF Adalimumab in HBc Antibody-Positive Psoriatic Arthritis Patients: A Retrospective Case Series of 8 Patients

Table 3

Previous reports about anti-TNF use in HBV active/inactive/occult carriers with psoriatic disease.

Study	Study type	PsA/Pso patients	Patients’ categories	Premedication	Anti-TNF	Followup; period	HBV reactivation
Cassano et al. 2011 [17]	R	34 PsA; 28 PsO	OC	No	44 ETA; 10 ADA; 8 IFX	About; 4 years	Reappearance of HBsAg without detectable HBV-DNA in 1 patient
Prignano et al. 2011 [18]	R	11 PsO	OC	No	ETA	7.8 months	No viral reactivation
Cho et al. 2012 [19]	R	5 PsA; 2 PsO	2 IC; 5 AC	1 patients had lamivudine and then entecavir	1 ADA; 6 ETA	26.6 months; (range 14–45)	3 patients had HBV reactivation
Fotiadou et al. 2011 [20]	R	7 PsO	IC	Lamivudine	3 ADA; 3 ETA; 1 IFX	6–24 months	1 patient; receiving IFX had increase of viral load up to 600 IU/mL

Psa: psoriatic arthritis; PsO: psoriasis; R: retrospective; OC: occult carrier; IC: inactive carrier; AC: active carriers; ADA: adalimumab; ETA: etanercept; IFX: infliximab.